Biology After AI

Inkef Capital and Nebius host a conversation on what's working and what's hype in AI x bio, on the first evening of Jefferies week (Monday 16 November). The invite list is techbio founders, early-stage and scale-up biotech teams, AI and data leaders from large pharma, and investors from life sciences and tech.

Questions on the table include whether AI biotechs are really getting cheaper to build and where defensibility sits: the model, proprietary data, the experimental loop or the resulting drug assets. 6pm to 10pm, free, with the exact address given on registration.

Why go: a room of techbio founders and investors comparing notes on defensibility, the question most decks skip. Best for AI x bio founders and the investors looking at them.